Navigation Links
Vitamin D found to fight placental infection
Date:12/1/2008

In a paper available at the online site of the journal Biology of Reproduction, a team of UCLA researchers reports for the first time that vitamin D induces immune responses in placental tissues by stimulating production of the antimicrobial protein cathelicidin.

The study involved exposing cultured human trophoblast cells to the active form of vitamin D, leading to production of cathelicidin and an increased antibacterial response in the trophoblast cells.

The team, headed by Dr. Martin Hewison, suspects that the ability of the placenta to synthesize cathelicidin varies widely among women. Their discovery suggests that placental innate immunity can be enhanced if pregnant women supplement their diets with vitamin D.

Induction of cathelicidin production by vitamin D may help the placenta stave off infection by a variety of pathogenic organisms, including staphylococcus, streptococcus, and E. coli bacteria. Vitamin D may also enhance and sustain this bacterial killing by protecting placental trophoblast cells from infection-associated cell death.

The significance of vitamin D in human reproduction has been recognized for the past 20 years, although its exact role has not been completely understood. This study presents a new mechanism for activation of innate immune responses in the placenta to protect it from infectious bacteria and sheds new light on the possible role of vitamin D in pregnancy and pregnancy-associated infection.


'/>"/>

Contact: Martin Hewison
mhewison@mednet.ucla.edu
Society for the Study of Reproduction
Source:Eurekalert

Page: 1

Related biology news :

1. Vitamin C lowers levels of inflammation biomarker considered predictor of heart disease
2. Could vitamin D save us from radiation?
3. Lung airway cells activate vitamin D and increase immune response
4. Optimal dose of vitamin E maximizes benefits, minimizes risk
5. Vitamin K does not stem BMD decline in postmenopausal women with osteopenia
6. Lack of vitamin D linked to Parkinsons disease
7. Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist
8. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
9. Dont forget the vitamin A when working with its carrier protein
10. Variant of vitamin D receptor gene linked to melanoma risk
11. Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion ... of bioprocess media products engineered to radically streamline culture processes, minimize processing ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. ... and expansion clinical trial for its lead drug candidate, AC0010, at the World ... trial was to determine the safety, antitumor activity, and recommended phase II dosage ...
(Date:12/7/2016)... /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces webcast ... the Company,s Annual and Special Meeting. The ... on Thursday, December 15, 2016 at Mount Royal ... 4825 Mount Royal Gate SW, Calgary, Alberta ... and management information circular, containing the matters to be considered ...
Breaking Biology Technology: